Committee Constituted For “National Drugs Database”

New Delhi : The Drugs Controller General (India) Dr V. G. Somani has constituted  a Committee to have a comprehensive “National Drugs Database” vide office memorandum F. No. ED/Misc./365/2022 dated 27.10.2022 of following members:-

  1. Dr. HG Koshia, Commissioner, FDCA, Gujarat
  2. Sh. AK Pradhan, JDC (I), Convenor
  3. Dr. Pooja Gupta, Addl. Professor, AIIMS, New Delhi
  4. Dr Jerian Jose, Scientist D, ICMR, New Delhi
  5. Sh. DR Gahane, JC, FDA, Maharashtra
  6. Sh. BT Khanapure, SDC, Karnataka and
  7. Sh. Navneet Marwaha, SDC, HP

This decision is taken to have a comprehensive database of drug formulations manufactured/ marketed in the country providing detailed information on the drug, its dosage form, strength, details of manufacturer/ marketer/importer etc. This will not only empower the consumers but also for improving the monitoring mechanism for quality of drugs in circulation, across the country and uniform administration of the regulatory system.

The committee will examine the existing database available with various Authorities like States/UT Drugs Control Depts, CDSCO, various manufacturer/ marketer/importer.

The committee will give recommendations & Prepare a comprehensive “National Drugs Database” of drug formulations manufactured/ marketed in the country providing detailed information on the drug, its dosage form, strength, details of manufacturer/ marketer/importer etc.

The committee may co opt any other expert, as deemed necessary.

The committee will submit its recommendations including “National Drugs Database” in three months.

  • Related Posts

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    Milan: CPHI Milan 2026, one of the pharmaceutical industry’s largest global events, has launched four specialist zones designed to connect pharmaceutical companies with the technologies, services and expertise shaping the…

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    Washington: Eli Lilly’s experimental weight-loss drug retatrutide has yet to be approved by the FDA. But the buzz surrounding the effectiveness of the compound—commonly known as triple-G—has already triggered a…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    CPHI Milan launches four special AI, cold chain, contamination control & labelling zones at this year’s event

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    Lilly takes 6 companies to court for selling retatrutide knockoffs

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

    FDA Busts Abortion Medicine Racket in Nagpur, Solapur; IndiaMART Directors among 8 Booked

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    Gleneagles BGS Hospital honours donor families with India’s largest organ donation recognition wall

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    NCB Uncovers Pharmaceutical Fentanyl Diversion Racket in Rural Punjab; Over 18,000 NDPS Drug Units Seized

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch

    Sun Pharma will Need HC Nod for Semaglutide Tablet Launch